Canada - engelsk - Health Canada

pharmascience inc - conjugated estrogens - tablet - 1.25mg - conjugated estrogens 1.25mg - estrogens

Canada - engelsk - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.3mg - conjugated estrogens 0.3mg - estrogens

Canada - engelsk - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.9mg - conjugated estrogens 0.9mg - estrogens

Den europeiske union - engelsk - EMA (European Medicines Agency)

pfizer europe ma eeig - oestrogens conjugated, bazedoxifene - postmenopause - conjugated estrogens and bazedoxifene - duavive is indicated for:treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.the experience treating women older than 65 years is limited.

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

theraskin farmaceutica ltda. - acetato de medroxiprogesterona, estrogÊnios conjugados - estrogenos assocs a outros farmacos exclusive androgenos

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorio aldo union s.l. - estrogenos conjugados - comprimido - 0,625 mg - estrogenos conjugados 0,625 mg - estrógenos conjugados

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 0.3 mg - menest is indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - female hypogonadism. female hypogonadism. - female castration. female castration. - primary ovarian failure. primary ovarian failure. - breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. breast cancer (for palliation only) in appropriately selected women and men with metastatic disease

USA - engelsk - NLM (National Library of Medicine)

avera mckennan hospital - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 0.625 mg

USA - engelsk - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg

USA - engelsk - NLM (National Library of Medicine)

leading pharmaceuticals, llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength are indicated in the treatment of: moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone full strength and esterified estrogens and methyltestosterone half strength have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warning). estrogens should not be used in women with any of the following conditions: 1.       known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. 2.       known or suspected estrogen-dependent neoplasia. 3.       known or suspected pregnancy (see boxed warning). 4.       undiagnosed abnormal genital bleeding. 5.       active thrombophlebitis or thromboembolic disorders. 6.       a past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previous estrogen use (except when in treatment of breast malignancy). methyltestosterone should not be used in: 1.       the presence of severe liver damage. 2.       pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or breast-fed infant.